^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
loperamide
i
Other names: JNJ-289679
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generic mfg.
Drug class:
µ-opioid agonist
Related drugs:
1d
Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome (clinicaltrials.gov)
P=N/A, N=258, Recruiting, Beijing Tiantan Hospital
New trial
|
loperamide
13d
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=57, Recruiting, Sun Yat-sen University
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib) • fulvestrant • AiRuiKang (dalpiciclib) • loperamide
14d
Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer. (PubMed, ESMO Open)
This analysis demonstrates the generally consistent, manageable and tolerable safety profile of inavolisib plus palbociclib-fulvestrant. Key selected adverse events were generally reversible and were controlled by concomitant medications and dose modifications.
P3 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
HR positive • HER-2 negative • PIK3CA mutation • HR positive + HER-2 negative
|
Ibrance (palbociclib) • fulvestrant • dexamethasone • metformin • Itovebi (inavolisib) • loperamide
1m
iRECOVER: Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance (clinicaltrials.gov)
P3, N=140, Recruiting, University Hospital, Basel, Switzerland | Not yet recruiting --> Recruiting
Enrollment open • HEOR
|
loperamide
1m
Effect of cationic amphiphilic drugs on mRNA lipoplex-induced protein expression. (PubMed, J Liposome Res)
The mRNA lipoplexes were formulated using a modified ethanol injection method and applied to human hepatoma HuH-7 cells, human prostate cancer PC-3 cells, and DC2.4 mouse dendritic cells in the presence of various CADs: ebastine (EBS), loperamide (LPM), carvedilol (CVD), nortriptyline (NRT), desloratadine (DSL), and chloroquine (CQ). However, EBS also diminishes antibody responses triggered by mRNA lipoplexes. Accordingly, caution is warranted when administering lipid-based mRNA vaccines to patients taking CADs, as these drugs may influence vaccine efficacy and safety.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
|
chloroquine phosphate • loperamide
2ms
Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial. (PubMed, Br J Cancer)
The triple combination showed moderate tolerability and termination occurred after the first stage of Phase II due to insufficient efficacy. Our findings highlight challenges in translating organoid-derived drug combinations to clinical practice.
P1/2 data • Journal
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
|
lapatinib • Mektovi (binimetinib) • vinorelbine tartrate • loperamide
2ms
Acacetin Alleviates Loperamide-Induced Functional Constipation by Inhibiting P53-Mediated Apoptosis in Colonic Epithelial Cells. (PubMed, Neurogastroenterol Motil)
Acacetin alleviates loperamide-induced FC by inhibiting P53-mediated apoptosis in colonic epithelial cells, providing new insights into the therapeutic mechanisms of traditional Chinese herbal medicine YWL in treating constipation.
Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
loperamide
2ms
Multi-System Analysis of Opioid Receptor Binding (clinicaltrials.gov)
P1, N=25, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting | N=60 --> 25 | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
loperamide
3ms
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients (clinicaltrials.gov)
P1, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
Trial completion date • Trial primary completion date • Checkpoint inhibition
|
loperamide
3ms
Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational study. (PubMed, Clin Transl Oncol)
Episodes of diarrhea were mostly graded 1-2 and no patients discontinued abemaciclib due to diarrhea. Patients reported high satisfaction with abemaciclib PSP, good adherence, and favorable quality of life, supporting the use of PSP in clinical practice.
Observational data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • EGFR positive
|
Verzenio (abemaciclib) • loperamide
4ms
SAFE-CAP: Rash & Diarrhea Prophylaxis With Capivasertib (clinicaltrials.gov)
P2, N=108, Not yet recruiting, Maryam Lustberg
New P2 trial
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
fulvestrant • Truqap (capivasertib) • loperamide
4ms
BoWell - Sb252: Saccharomyces boulardii CNCM I-745 in Irritable Bowel Syndrome. (2024-520276-10-00)
P2/3, N=365, Recruiting, Biocodex
New P2/3 trial
|
loperamide
Share via
